Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia

Acalabrutinib is a selective irreversible Bruton tyrosine kinase (BTK) inhibitor that does not affect IL2-associated tyrosine kinase or antibody-dependent cellular cytotoxicity, making it an attractive candidate for combination therapy with anti-CD20 antibodies. We investigated acalabrutinib plus ob...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Cancer Discov
Main Authors: Woyach, Jennifer A., Blachly, James S., Rogers, Kerry A., Bhat, Seema A., Jianfar, Mojgan, Lozanski, Gerard, Weiss, David M., Andersen, Barbara L., Gulrajani, Michael, Frigault, Melanie M., Hamdy, Ahmed, Izumi, Raquel, Munugalavadla, Veerendra, Quah, Cheng, Wang, Min-Hui, Byrd, John C.
Format: Artigo
Sprog:Inglês
Udgivet: 2020
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8176161/
https://ncbi.nlm.nih.gov/pubmed/31915195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-19-1130
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker